<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8"/>
  <meta name="viewport" content="width=device-width,initial-scale=1.0"/>
  <title>Genesis‑T1D‑RxM‑18 — Static Pitch Deck</title>
  <style>
    html,body{
      margin:0;
      padding:0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", sans-serif;
      background: #020617;
      color:#f5f5f5;
      scroll-behavior: smooth;
    }
    .slide{
      min-height:100vh;
      display:flex;
      align-items:center;
      justify-content:center;
      padding:3rem 1.5rem;
      box-sizing:border-box;
    }
    .container{
      max-width:1152px;
      width:100%;
    }
    h1,h2,h3,h4,h5,h6{
      margin:0;
      font-weight:600;
    }
    h1{
      font-size:3rem;
      line-height:1.2;
    }
    h2{
      font-size:2.5rem;
      line-height:1.3;
    }
    h3{
      font-size:1.5rem;
    }
    p{
      line-height:1.6;
      margin:0.5rem 0;
    }
    .center{text-align:center;}
    .grid{
      display:grid;
      gap:2rem;
    }
    @media(min-width:768px){
      .md-3-cols{grid-template-columns:repeat(3,1fr);}
      .md-2-cols{grid-template-columns:repeat(2,1fr);}
      .md-4-cols{grid-template-columns:repeat(4,1fr);}
    }
    .card{
      padding:1.5rem;
      border-radius:0.75rem;
      border:1px solid rgba(255,255,255,0.1);
      background:rgba(255,255,255,0.03);
    }
    .circle{
      width:1rem;
      height:1rem;
      border-radius:50%;
      display:inline-block;
      margin-right:0.5rem;
    }
    .grad-cyan-purple{
      background:linear-gradient(90deg,#0ea5e9,#8b5cf6);
      -webkit-background-clip:text;
      -webkit-text-fill-color:transparent;
    }
    .grad-red-yellow{
      background:linear-gradient(90deg,#f43f5e,#f59e0b);
      -webkit-background-clip:text;
      -webkit-text-fill-color:transparent;
    }
    .grad-green-cyan{
      background:linear-gradient(90deg,#22c55e,#06b6d4);
      -webkit-background-clip:text;
      -webkit-text-fill-color:transparent;
    }
    .grad-purple-pink{
      background:linear-gradient(90deg,#a855f7,#ec4899);
      -webkit-background-clip:text;
      -webkit-text-fill-color:transparent;
    }
    .grad-cyan-pink{
      background:linear-gradient(90deg,#0ea5e9,#ec4899);
      -webkit-background-clip:text;
      -webkit-text-fill-color:transparent;
    }
    .timeline{
      display:flex;
      align-items:flex-start;
      margin-bottom:1rem;
    }
    .timeline .icon{
      flex-shrink:0;
      width:3rem;
      height:3rem;
      border-radius:50%;
      display:flex;
      align-items:center;
      justify-content:center;
      color:#fff;
      background:linear-gradient(90deg,#0ea5e9,#8b5cf6);
      margin-right:1rem;
      font-weight:bold;
    }
    .table-wrapper{ overflow-x:auto; }
    table{ width:100%; border-collapse:collapse; }
    th,td{ padding:0.75rem 1rem; text-align:left; }
    thead th{ background:#0f172a; }
    tbody tr:nth-child(odd){ background:#0f172a; }
    tbody tr:nth-child(even){ background:#111827; }
    .status-pass{color:#38bdf8;}
    .status-excellent{color:#22c55e;}
    .status-strong{color:#06b6d4;}
  </style>
</head>
<body>
  <!-- Project Summary Slide -->
  <section id="project-summary" class="slide">
    <div class="container center">
      <h1 class="grad-cyan-pink">Genesis‑T1D‑RxM‑18</h1>
      <p class="center" style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">
        A first‑in‑class immunomodulatory small molecule (PD‑L1) for Type 1 Diabetes — developed by Genesis Molecular Engine. Inventor: <strong>Ebenezer Babasola — The Origin Mirror</strong>.
      </p>
      <div class="grid md-3-cols" style="margin-top:3rem;">
        <div class="card center">
          <span class="circle" style="background:#06b6d4;"></span>
          <h3 style="color:#06b6d4;margin-top:0.5rem;">Checkpoint Modulator</h3>
          <p style="color:#d1d5db;">Designed to prevent autoimmune β‑cell destruction via PD‑L1</p>
        </div>
        <div class="card center">
          <span class="circle" style="background:#a855f7;"></span>
          <h3 style="color:#a855f7;margin-top:0.5rem;">Disease‑Modifying</h3>
          <p style="color:#d1d5db;">Potential to reduce insulin dependence or halt progression</p>
        </div>
        <div class="card center">
          <span class="circle" style="background:#ec4899;"></span>
          <h3 style="color:#ec4899;margin-top:0.5rem;">Oral Candidate</h3>
          <p style="color:#d1d5db;">Drug‑like profile and oral formulation potential</p>
        </div>
      </div>
      <div class="card" style="margin-top:3rem;background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
        <h4 style="color:#06b6d4;margin-bottom:1rem;">Key Performance Metrics</h4>
        <div class="grid md-3-cols" style="color:white;">
          <div>
            <div style="font-size:1.75rem;">–9.1 kcal/mol</div>
            <div style="font-size:0.875rem;color:#9ca3af;">Docking Score (PD‑L1)</div>
          </div>
          <div>
            <div style="font-size:1.75rem;">0.83</div>
            <div style="font-size:0.875rem;color:#9ca3af;">QED (drug‑likeness)</div>
          </div>
          <div>
            <div style="font-size:1.75rem;">3.1</div>
            <div style="font-size:0.875rem;color:#9ca3af;">LogP (oral bioavailability)</div>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Unmet Need Slide -->
  <section id="unmet-need" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-red-yellow">Problem</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Type 1 Diabetes affects <strong>9M+ people globally</strong>. No cure exists — patients rely on lifelong insulin therapy while immune‑mediated β‑cell destruction remains unaddressed. Estimated market size ≈ <strong>$30B</strong> (2025).</p>
      </div>
      <div class="grid md-3-cols" style="margin-top:2rem;">
        <div class="card center" style="background:rgba(239,68,68,0.05);border-color:rgba(239,68,68,0.2);">
          <span class="circle" style="background:#ef4444;width:1.5rem;height:1.5rem;margin:0 auto;"></span>
          <h3 style="color:#ef4444;">Status Quo</h3>
          <p style="color:#d1d5db;">Insulin manages glucose but not autoimmune root cause</p>
        </div>
        <div class="card center" style="background:rgba(234,179,8,0.05);border-color:rgba(234,179,8,0.2);">
          <span class="circle" style="background:#facc15;width:1.5rem;height:1.5rem;margin:0 auto;"></span>
          <h3 style="color:#facc15;">Unmet Need</h3>
          <p style="color:#d1d5db;">No approved disease‑modifying small‑molecule therapies</p>
        </div>
        <div class="card center" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
          <span class="circle" style="background:#22c55e;width:1.5rem;height:1.5rem;margin:0 auto;"></span>
          <h3 style="color:#22c55e;">Opportunity</h3>
          <p style="color:#d1d5db;">PD‑L1 checkpoint modulation represents a white‑space</p>
        </div>
      </div>
      <div class="card" style="margin-top:2rem;background:rgba(31,41,55,0.5);border-color:#374151;">
        <h4 style="color:#f5f5f5;text-align:center;margin-bottom:1rem;">Market Opportunity</h4>
        <div class="grid md-2-cols">
          <div style="padding-right:1rem;">
            <h5 style="color:#06b6d4;">Scale</h5>
            <ul style="color:#d1d5db;margin-top:0.5rem;">
              <li>• 9M+ global patients</li>
              <li>• Rising incidence</li>
              <li>• Significant lifetime cost per patient</li>
            </ul>
          </div>
          <div style="padding-left:1rem;">
            <h5 style="color:#a855f7;">Value</h5>
            <ul style="color:#d1d5db;margin-top:0.5rem;">
              <li>• ~$30B annual global spend</li>
              <li>• 1% penetration ≈ $300M revenue</li>
              <li>• First‑in‑class positioning</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Solution Slide -->
  <section id="solution" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-cyan-purple">Our Solution</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Genesis‑T1D‑RxM‑18 — a novel <strong>PD‑L1 checkpoint modulator</strong> designed to prevent autoimmune β‑cell destruction.</p>
      </div>
      <div class="grid md-3-cols" style="margin-top:2rem;">
        <div class="card center" style="background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
          <div class="circle" style="background:#06b6d4;width:2rem;height:2rem;display:flex;align-items:center;justify-content:center;color:#000;margin:0 auto;">1</div>
          <h3 style="color:#06b6d4;margin-top:0.5rem;">First‑in‑Class</h3>
          <p style="color:#d1d5db;">Novel checkpoint modulation mechanism for autoimmune control</p>
        </div>
        <div class="card center" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
          <div class="circle" style="background:#8b5cf6;width:2rem;height:2rem;display:flex;align-items:center;justify-content:center;color:#000;margin:0 auto;">2</div>
          <h3 style="color:#8b5cf6;margin-top:0.5rem;">Oral Delivery</h3>
          <p style="color:#d1d5db;">Drug‑like profile (QED 0.83, LogP 3.1) supports oral dosing</p>
        </div>
        <div class="card center" style="background:rgba(236,72,153,0.05);border-color:rgba(236,72,153,0.2);">
          <div class="circle" style="background:#ec4899;width:2rem;height:2rem;display:flex;align-items:center;justify-content:center;color:#000;margin:0 auto;">3</div>
          <h3 style="color:#ec4899;margin-top:0.5rem;">Disease‑Modifying</h3>
          <p style="color:#d1d5db;">Potential to reduce insulin dependence and halt progression</p>
        </div>
      </div>
      <div class="card" style="margin-top:2rem;background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
        <h4 style="color:#f5f5f5;text-align:center;margin-bottom:1rem;">Mechanism of Action</h4>
        <div class="grid md-2-cols">
          <div style="padding-right:1rem;">
            <h5 style="color:#06b6d4;">PD‑L1 Targeting</h5>
            <p style="color:#d1d5db;">Modulates PD‑L1 to restore immune tolerance and protect β‑cells.</p>
          </div>
          <div style="padding-left:1rem;">
            <h5 style="color:#8b5cf6;">Immune Rebalancing</h5>
            <p style="color:#d1d5db;">Promotes regulatory T‑cell function while reducing inflammatory responses.</p>
          </div>
        </div>
      </div>
      <div class="card" style="margin-top:2rem;background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);text-align:center;">
        <h4 style="color:#22c55e;margin-bottom:0.5rem;">Competitive Advantage</h4>
        <p style="color:#f5f5f5;">Targets the underlying autoimmune process rather than only symptoms</p>
      </div>
    </div>
  </section>

  <!-- Validation Slide -->
  <section id="validation" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-green-cyan">In Silico Validation</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Docking, drug‑likeness, and safety predictions support advancement</p>
      </div>
      <div class="card" style="overflow:hidden;margin-top:2rem;background:rgba(15,23,42,0.8);border-color:#374151;">
        <div style="background:linear-gradient(90deg,rgba(56,189,248,0.2),rgba(139,92,246,0.2));padding:1rem;">
          <h3 style="color:#f5f5f5;">Computational Validation Results</h3>
        </div>
        <div class="table-wrapper">
          <table>
            <thead>
              <tr>
                <th style="color:#06b6d4;">Parameter</th>
                <th style="color:#8b5cf6;">Value</th>
                <th style="color:#ec4899;">Target</th>
                <th style="color:#22c55e;">Status</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td style="color:#d1d5db;">Docking Score (PD‑L1)</td>
                <td style="color:#fff;">−9.1 kcal/mol</td>
                <td style="color:#9ca3af;">&lt; −7</td>
                <td class="status-strong">Strong</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">QED</td>
                <td style="color:#fff;">0.83</td>
                <td style="color:#9ca3af;">&gt; 0.5</td>
                <td class="status-excellent">Excellent</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">LogP</td>
                <td style="color:#fff;">3.1</td>
                <td style="color:#9ca3af;">&lt; 5</td>
                <td class="status-pass">Pass</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">Toxicity (ProTox‑II)</td>
                <td style="color:#fff;">Low</td>
                <td style="color:#9ca3af;">Low Risk</td>
                <td class="status-pass">Pass</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">Novelty vs DrugBank</td>
                <td style="color:#fff;">100% novel</td>
                <td style="color:#9ca3af;">Tanimoto &lt; 0.4</td>
                <td class="status-pass">Pass</td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>
      <div class="grid md-3-cols" style="margin-top:2rem;">
        <div class="card center" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
          <h4 style="color:#22c55e;margin-bottom:0.5rem;">Drug‑Likeness</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Favorable profile for oral small‑molecule development</p>
        </div>
        <div class="card center" style="background:rgba(59,130,246,0.05);border-color:rgba(59,130,246,0.2);">
          <h4 style="color:#3b82f6;margin-bottom:0.5rem;">Safety</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Low predicted toxicity across endpoints</p>
        </div>
        <div class="card center" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
          <h4 style="color:#8b5cf6;margin-bottom:0.5rem;">Target Affinity</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Consistent in‑silico affinity to PD‑L1</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Novelty & IP Slide -->
  <section id="novelty" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-cyan-green">Novelty & Intellectual Property</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Comprehensive IP protection with blockchain‑secured provenance</p>
      </div>
      <div class="grid md-2-cols" style="margin-top:2rem;">
        <div class="space-y-6">
          <div class="card" style="background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
            <div style="display:flex;align-items:center;margin-bottom:0.75rem;">
              <span class="circle" style="background:#06b6d4;"></span>
              <h3 style="color:#06b6d4;margin-left:0.75rem;">Novelty</h3>
            </div>
            <p style="color:#d1d5db;">Tanimoto similarity vs DrugBank below threshold; structure considered <strong style="color:#fff;">100% novel</strong>.</p>
          </div>
          <div class="card" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
            <div style="display:flex;align-items:center;margin-bottom:0.75rem;">
              <span class="circle" style="background:#22c55e;"></span>
              <h3 style="color:#22c55e;margin-left:0.75rem;">Licensing Options</h3>
            </div>
            <p style="color:#d1d5db;">Exclusive, outright sale, or tokenized DAO IP‑NFT.</p>
          </div>
        </div>
        <div class="space-y-6">
          <div class="card" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
            <div style="display:flex;align-items:center;margin-bottom:0.75rem;">
              <span class="circle" style="background:#8b5cf6;"></span>
              <h3 style="color:#8b5cf6;margin-left:0.75rem;">Blockchain Protection</h3>
            </div>
            <p style="color:#d1d5db;">SHA‑256 + IPFS timestamped record (IP‑NFT)</p>
            <p style="font-size:0.875rem;color:#9ca3af;margin-top:0.5rem;">Patent Hash:</p>
            <p style="font-size:0.875rem;color:#fff;word-break:break-all;">f8a667daadcc8a4385ffe17dad253a6e2ee1ef82d09eeb50806a591590930198</p>
          </div>
          <div class="card" style="background:rgba(236,72,153,0.05);border-color:rgba(236,72,153,0.2);">
            <div style="display:flex;align-items:center;margin-bottom:0.75rem;">
              <span class="circle" style="background:#ec4899;"></span>
              <h3 style="color:#ec4899;margin-left:0.75rem;">Patent Strategy</h3>
            </div>
            <p style="color:#d1d5db;">Provisional patent → Utility patent; US/EU/CA with PCT coverage.</p>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Roadmap Slide -->
  <section id="roadmap" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-purple-pink">Development Roadmap</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">From in‑silico to IND filing</p>
      </div>
      <div style="margin-top:2rem;">
        <div class="timeline">
          <div class="icon">1</div>
          <div class="card" style="flex:1;background:rgba(31,41,55,0.5);border-color:#374151;">
            <div style="display:flex;flex-direction:column;gap:0.25rem;margin-bottom:0.5rem;">
              <span style="color:#f5f5f5;font-weight:600;">Now</span>
              <span style="color:#a855f7;font-size:0.875rem;">In‑silico validation</span>
            </div>
            <div style="color:#06b6d4;margin-bottom:0.5rem;">Current</div>
            <p style="color:#d1d5db;">Docking, ADMET, novelty, and safety predictions</p>
          </div>
        </div>
        <div class="timeline">
          <div class="icon">2</div>
          <div class="card" style="flex:1;background:rgba(31,41,55,0.5);border-color:#374151;">
            <div style="display:flex;flex-direction:column;gap:0.25rem;margin-bottom:0.5rem;">
              <span style="color:#f5f5f5;font-weight:600;">Next 12–18 Months</span>
              <span style="color:#a855f7;font-size:0.875rem;">In vitro assays</span>
            </div>
            <div style="color:#06b6d4;margin-bottom:0.5rem;">β‑cell protection &amp; PD‑L1 modulation</div>
            <p style="color:#d1d5db;">CRO partnerships; early tox and selectivity</p>
          </div>
        </div>
        <div class="timeline">
          <div class="icon">3</div>
          <div class="card" style="flex:1;background:rgba(31,41,55,0.5);border-color:#374151;">
            <div style="display:flex;flex-direction:column;gap:0.25rem;margin-bottom:0.5rem;">
              <span style="color:#f5f5f5;font-weight:600;">Year 2</span>
              <span style="color:#a855f7;font-size:0.875rem;">Preclinical (in vivo + tox)</span>
            </div>
            <div style="color:#06b6d4;margin-bottom:0.5rem;">PK/PD &amp; safety</div>
            <p style="color:#d1d5db;">Efficacy in relevant models; dose finding</p>
          </div>
        </div>
        <div class="timeline">
          <div class="icon">4</div>
          <div class="card" style="flex:1;background:rgba(31,41,55,0.5);border-color:#374151;">
            <div style="display:flex;flex-direction:column;gap:0.25rem;margin-bottom:0.5rem;">
              <span style="color:#f5f5f5;font-weight:600;">Year 3</span>
              <span style="color:#a855f7;font-size:0.875rem;">IND filing</span>
            </div>
            <div style="color:#06b6d4;margin-bottom:0.5rem;">Regulatory prep</div>
            <p style="color:#d1d5db;">Complete IND‑enabling studies; file for Phase 1</p>
          </div>
        </div>
      </div>
      <div class="grid md-3-cols" style="margin-top:3rem;">
        <div class="card center" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
          <h4 style="color:#22c55e;margin-bottom:0.5rem;">12‑18 Months</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">In vitro validation &amp; early tox</p>
        </div>
        <div class="card center" style="background:rgba(59,130,246,0.05);border-color:rgba(59,130,246,0.2);">
          <h4 style="color:#3b82f6;margin-bottom:0.5rem;">Regulatory Ready</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">IND path established</p>
        </div>
        <div class="card center" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
          <h4 style="color:#8b5cf6;margin-bottom:0.5rem;">Partnership</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">License, co‑dev, or IP‑NFT</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Funding Slide -->
  <section id="funding" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-green-cyan">The Ask</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Seed funding to advance in vitro validation and prepare for preclinical</p>
      </div>
      <div class="center" style="margin-top:2rem;">
        <div style="font-size:3rem;" class="grad-green-cyan">$500K – $1M</div>
        <div style="color:#d1d5db;font-size:1.25rem;">Seed round</div>
        <p style="color:#9ca3af;max-width:700px;margin:1rem auto;">Funds allocated to CRO partnerships (assays), patent expansion (US, EU, CA, PCT), and preclinical development setup.</p>
      </div>
      <div class="grid md-3-cols" style="margin-top:2rem;">
        <div class="card center" style="background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
          <div style="font-size:1.25rem;color:#06b6d4;">CRO Partnerships</div>
          <h3 style="color:#06b6d4;margin-top:0.5rem;">Immunology Assays</h3>
          <p style="color:#d1d5db;font-size:0.875rem;">β‑cell protection and PD‑L1 modulation studies</p>
          <div style="color:#9ca3af;font-size:0.875rem;">Priority Use</div>
        </div>
        <div class="card center" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
          <div style="font-size:1.25rem;color:#8b5cf6;">Patent Expansion</div>
          <h3 style="color:#8b5cf6;margin-top:0.5rem;">US/EU/CA + PCT</h3>
          <p style="color:#d1d5db;font-size:0.875rem;">Broaden protection; maintain IP‑NFT record</p>
          <div style="color:#9ca3af;font-size:0.875rem;">Core Use</div>
        </div>
        <div class="card center" style="background:rgba(236,72,153,0.05);border-color:rgba(236,72,153,0.2);">
          <div style="font-size:1.25rem;color:#ec4899;">Preclinical Setup</div>
          <h3 style="color:#ec4899;margin-top:0.5rem;">Tox &amp; PK/PD</h3>
          <p style="color:#d1d5db;font-size:0.875rem;">Pathway to IND‑enabling package</p>
          <div style="color:#9ca3af;font-size:0.875rem;">Strategic Use</div>
        </div>
      </div>
      <div class="card" style="margin-top:2rem;background:rgba(31,41,55,0.5);border-color:#374151;">
        <h4 style="color:#f5f5f5;text-align:center;margin-bottom:1rem;">Value Proposition</h4>
        <div class="grid md-2-cols">
          <div style="padding-right:1rem;">
            <h5 style="color:#22c55e;">Commercial</h5>
            <ul style="color:#d1d5db;font-size:0.875rem;margin-top:0.5rem;">
              <li>• First‑in‑class small‑molecule approach in T1D</li>
              <li>• Multiple licensing and co‑dev paths</li>
              <li>• Platform potential across autoimmune diseases</li>
            </ul>
          </div>
          <div style="padding-left:1rem;">
            <h5 style="color:#06b6d4;">Scientific</h5>
            <ul style="color:#d1d5db;font-size:0.875rem;margin-top:0.5rem;">
              <li>• Strong in‑silico signals (affinity, QED, LogP)</li>
              <li>• Clear validation plan with CROs</li>
              <li>• Robust IP with blockchain provenance</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- Valuation & Business Model Slide (kept in existing design slots) -->
  <section id="valuation" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-cyan-purple">Valuation & Business Model</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Scenario‑based valuation and flexible monetization</p>
      </div>
      <div class="card" style="margin-top:2rem;background:rgba(15,23,42,0.8);border-color:#374151;">
        <div class="table-wrapper">
          <table>
            <thead>
              <tr>
                <th style="color:#06b6d4;">Stage</th>
                <th style="color:#8b5cf6;">License</th>
                <th style="color:#ec4899;">Acquisition</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td style="color:#d1d5db;">In‑silico (now)</td>
                <td style="color:#fff;">$3M–$7M</td>
                <td style="color:#fff;">$5M–$15M</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">In vitro</td>
                <td style="color:#fff;">$10M–$20M</td>
                <td style="color:#fff;">$20M–$30M</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">IND‑ready</td>
                <td style="color:#fff;">$30M–$60M</td>
                <td style="color:#fff;">$50M–$100M</td>
              </tr>
              <tr>
                <td style="color:#d1d5db;">Phase 2 clinical</td>
                <td style="color:#fff;">$250M+</td>
                <td style="color:#fff;">$500M+</td>
              </tr>
            </tbody>
          </table>
        </div>
      </div>
      <div class="grid md-3-cols" style="margin-top:2rem;">
        <div class="card center" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
          <h4 style="color:#22c55e;margin-bottom:0.5rem;">Exclusive License</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Upfront + royalties</p>
        </div>
        <div class="card center" style="background:rgba(59,130,246,0.05);border-color:rgba(59,130,246,0.2);">
          <h4 style="color:#3b82f6;margin-bottom:0.5rem;">Outright Sale</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Immediate transfer</p>
        </div>
        <div class="card center" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
          <h4 style="color:#8b5cf6;margin-bottom:0.5rem;">DAO IP‑NFT</h4>
          <p style="color:#d1d5db;font-size:0.875rem;">Fractionalized biotech ownership</p>
        </div>
      </div>
    </div>
  </section>

  <!-- Contact Slide -->
  <section id="contact" class="slide">
    <div class="container">
      <div class="center">
        <h2 class="grad-cyan-purple">Contact</h2>
        <p style="color:#d1d5db;font-size:1.25rem;max-width:820px;margin:1rem auto;">Data room, docking files, and receptor structures available upon request</p>
      </div>
      <div class="grid md-2-cols" style="margin-top:2rem;gap:3rem;">
        <div class="space-y-6">
          <div class="card" style="background:rgba(56,189,248,0.05);border-color:rgba(56,189,248,0.2);">
            <h3 style="color:#06b6d4;margin-bottom:1rem;">Contact Information</h3>
            <div style="color:#d1d5db;">
              <h4 style="color:#fff;margin-bottom:0.25rem;">Ebenezer Babasola — The Origin Mirror</h4>
              <p style="color:#d1d5db;font-size:0.875rem;">Inventor &amp; Founder</p>
            </div>
            <div style="margin-top:1rem;">
              <p style="color:#a855f7;font-size:0.875rem;">Genesis Molecular Engine</p>
              <p style="color:#d1d5db;font-size:0.875rem;">Toronto, ON</p>
            </div>
            <div style="margin-top:1rem;">
              <a href="mailto:ebenezeerbabs@gmail.com" style="color:#06b6d4;text-decoration:underline;">ebenezeerbabs@gmail.com</a>
            </div>
          </div>
          <div class="card" style="background:rgba(139,92,246,0.05);border-color:rgba(139,92,246,0.2);">
            <h3 style="color:#8b5cf6;margin-bottom:0.5rem;">Next Steps</h3>
            <ul style="color:#d1d5db;font-size:0.875rem;margin-top:0.5rem;">
              <li style="display:flex;align-items:center;margin-bottom:0.5rem;"><span class="circle" style="background:#06b6d4;width:0.5rem;height:0.5rem;margin-right:0.5rem;"></span>Schedule partnership discussion</li>
              <li style="display:flex;align-items:center;margin-bottom:0.5rem;"><span class="circle" style="background:#8b5cf6;width:0.5rem;height:0.5rem;margin-right:0.5rem;"></span>Review detailed technical data</li>
              <li style="display:flex;align-items:center;"><span class="circle" style="background:#ec4899;width:0.5rem;height:0.5rem;margin-right:0.5rem;"></span>Finalize funding agreement</li>
            </ul>
          </div>
        </div>
        <div class="space-y-6">
          <div class="card" style="background:rgba(34,197,94,0.05);border-color:rgba(34,197,94,0.2);">
            <h3 style="color:#22c55e;margin-bottom:1rem;">Why Partner With Us</h3>
            <div class="space-y-4" style="color:#d1d5db;font-size:0.875rem;">
              <div style="display:flex;align-items:flex-start;">
                <span class="circle" style="background:#22c55e;width:0.5rem;height:0.5rem;margin-right:0.5rem;margin-top:0.25rem;"></span>
                <div>
                  <h4 style="color:#fff;font-size:0.875rem;margin-bottom:0.25rem;">AI‑Driven Discovery</h4>
                  <p style="color:#9ca3af;font-size:0.75rem;">Genesis Molecular Engine</p>
                </div>
              </div>
              <div style="display:flex;align-items:flex-start;">
                <span class="circle" style="background:#06b6d4;width:0.5rem;height:0.5rem;margin-right:0.5rem;margin-top:0.25rem;"></span>
                <div>
                  <h4 style="color:#fff;font-size:0.875rem;margin-bottom:0.25rem;">Strong IP</h4>
                  <p style="color:#9ca3af;font-size:0.75rem;">Patent + Blockchain provenance</p>
                </div>
              </div>
              <div style="display:flex;align-items:flex-start;">
                <span class="circle" style="background:#8b5cf6;width:0.5rem;height:0.5rem;margin-right:0.5rem;margin-top:0.25rem;"></span>
                <div>
                  <h4 style="color:#fff;font-size:0.875rem;margin-bottom:0.25rem;">Flexible Deals</h4>
                  <p style="color:#9ca3af;font-size:0.75rem;">License, sale, or DAO IP‑NFT</p>
                </div>
              </div>
            </div>
          </div>
          <div class="card center" style="background:rgba(31,41,55,0.5);border-color:#374151;">
            <h4 style="color:#f5f5f5;margin-bottom:0.5rem;">Ready to Collaborate?</h4>
            <p style="color:#d1d5db;font-size:0.875rem;margin-bottom:1rem;">Let’s bring a disease‑modifying therapy to patients</p>
            <a href="mailto:ebenezeerbabs@gmail.com?subject=Genesis‑T1D‑RxM‑18%20Partnership%20Inquiry" style="display:inline-block;background:linear-gradient(90deg,#06b6d4,#8b5cf6);color:#fff;padding:0.75rem 2rem;border-radius:0.5rem;text-decoration:none;">Start the Conversation</a>
          </div>
        </div>
      </div>
      <div style="text-align:center;padding:2rem 0;border-top:1px solid #374151;margin-top:2rem;">
        <p style="color:#9ca3af;font-size:0.875rem;">© 2025 Genesis Molecular Engine. All rights reserved.</p>
      </div>
    </div>
  </section>
</body>
</html>
